{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=34", "query": { "intervention": "Level B", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 1433, "total_pages": 144, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T09:31:25.931Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00646035", "title": "A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "End Stage Renal Disease" ], "interventions": [ { "name": "paricalcitol capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-03-28", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 22, "location_summary": "Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00646035" }, { "nct_id": "NCT02736825", "title": "Simulines Non-Inferiority Pivotal Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Skin Laxity" ], "interventions": [ { "name": "Ulthera System with standard transducer", "type": "DEVICE" }, { "name": "Ulthera System with prototype 2 simulines transducer", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Ulthera, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "30 Years to 70 Years" }, "enrollment_count": 262, "start_date": "2016-04-11", "completion_date": "2017-04-25", "has_results": true, "last_update_posted_date": "2020-02-19", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 8, "location_summary": "Beverly Hills, California • Roseville, California • Sacramento, California + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02736825" }, { "nct_id": "NCT05790668", "title": "Motivational Refinements for Facilitating Reinforcement Schedule Thinning", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Decreasing Destructive Behavior", "Increasing Functional Communicative Behavior" ], "interventions": [ { "name": "Traditional Schedule Thinning", "type": "BEHAVIORAL" }, { "name": "PIA-Informed Schedule Thinning", "type": "BEHAVIORAL" }, { "name": "PIA-Informed Schedule Thinning with Competing Stimuli", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 30, "start_date": "2023-10-24", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • Somerset, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Somerset", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05790668" }, { "nct_id": "NCT05440708", "title": "A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "TTI-101", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tvardi Therapeutics, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 193, "start_date": "2023-03-23", "completion_date": "2027-07-20", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05440708" }, { "nct_id": "NCT01884285", "title": "AZD8186 First Time In Patient Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Castrate-resistant Prostate Cancer CRPC", "Squamous Non-Small Cell Lung Cancer sqNSCLC", "Triple Negative Breast Cancer TNBC" ], "interventions": [ { "name": "Part A: AZD8186 monotherapy", "type": "DRUG" }, { "name": "Part B: AZD8186 monotherapy", "type": "DRUG" }, { "name": "Part C1: Abiraterone acetate combination with AZD8186", "type": "DRUG" }, { "name": "Part D1: AZD2014 combination with AZD8186", "type": "DRUG" }, { "name": "Part D2 AZD2014 combination with AZD8186", "type": "DRUG" }, { "name": "Part C2: Abiraterone acetate combination with AZD8186", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 147, "start_date": "2013-07-09", "completion_date": "2020-02-07", "has_results": false, "last_update_posted_date": "2020-05-29", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01884285" }, { "nct_id": "NCT03496662", "title": "BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "BMS-813160", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Peripheral blood", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-08-31", "completion_date": "2024-07-25", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03496662" }, { "nct_id": "NCT06482905", "title": "Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High-grade Glioma", "WHO Grade Ⅳ Glioma" ], "interventions": [ { "name": "Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Tcelltech Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 52, "start_date": "2024-09-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06482905" }, { "nct_id": "NCT00823433", "title": "Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Group B Streptococcus" ], "interventions": [ { "name": "oral penicillin V", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corewell Health East", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 25, "start_date": "2009-01", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2016-11-04", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 1, "location_summary": "Royal Oak, Michigan", "locations": [ { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00823433" }, { "nct_id": "NCT06747858", "title": "Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis", "CFTR Gene Mutation" ], "interventions": [ { "name": "ARCT-032", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Arcturus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-12-12", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 13, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06747858" }, { "nct_id": "NCT03377023", "title": "Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Lung Cancer, Nonsmall Cell", "Non Small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2018-02-02", "completion_date": "2026-08", "has_results": true, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-26T09:31:25.931Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03377023" } ] }